Loading clinical trials...
Loading clinical trials...
COVID-19 Outpatient Thrombosis Prevention Trial A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID Adults Not Requiring Hospitalization at Time of Diagnosis
Conditions
Interventions
Apixaban 2.5 MG
Apixaban 5MG
+2 more
Locations
71
United States
University of Southern California
Los Angeles, California, United States
Stanford University School of Medicine
Palo Alto, California, United States
Zuckerberg San Francisco General
San Francisco, California, United States
Olive View-UCLA Medical Center
Sylmar, California, United States
Pine Ridge Family Medicine
Colorado Springs, Colorado, United States
Life Tree Health, Inc.
Washington D.C., District of Columbia, United States
Start Date
September 7, 2020
Primary Completion Date
August 5, 2021
Completion Date
August 5, 2021
Last Updated
February 17, 2022
NCT06631287
NCT05101213
NCT04565665
NCT06871293
NCT04978571
NCT06082518
Lead Sponsor
Frank C Sciurba
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions